• Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
Home News & Views Category: ASX

Investor Briefing – TheraPharm GmbH Acquisition

Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition.
Read more

Investor Conference Call: Telix’s acquisition of TheraPharm GmbH

Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm GmbH.
Read more

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.
Read more

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)
Read more

Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership

Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future
Read more

Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market.
Read more

Activity Report and Sales Note to Accompany Appendix 4C

Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.
Read more

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma
Read more

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)
Read more

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Telix announces it has entered into a strategic collaboration agreement with Varian Medical Systems
Read more

Posts pagination

Previous page 1 … 21 22 23 … 27 Next page
  • Our Company
  • Our Portfolio
  • Investor Center
  • News & Views
  • Careers
  • Contact Us
  • Telix Hotline
  • Legal Notices

Subscribe to our newsletter to stay in the loop

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.​
The Telix Pharmaceuticals, the Illuccix and Gozellix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.​
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.​

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Consumer Health Privacy Notice
  • Privacy Settings

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”